Global Dendritic Cell Cancer Vaccine Market Insights, Forecast to 2028

Publisher Name :
Date: 16-Mar-2022
No. of pages: 116
Inquire Before Buying

Dendritic Cell Cancer Vaccine market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Dendritic Cell Cancer Vaccine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.

Segment by Type

- CreaVax

- Sipuleucel-T (Provenge)

- Others

Segment by Application

- Pediatrics

- Adults

By Company

- Activarti

- Argos Therapeutics

- SOTIO (Acquired by PPF Group)

- Bellicum Pharmaceuticals

- JW CreaGene

- DanDrit

- DCPrime

- Elios Therapeutics

- ImmunoCellular Therapeutics

- Kiromic

- Medigene

- Merck

- Northwest Biotherapeutics

- Immutep Limited

- Dendreon Corporation

- Oncobiomed

By Region

- North America

- - U.S.

- - Canada

- Europe

- - Germany

- - France

- - U.K.

- - Italy

- - Russia

- Asia-Pacific

- - China

- - Japan

- - South Korea

- - India

- - Australia

- - Taiwan

- - Indonesia

- - Thailand

- - Malaysia

- - Philippines

- - Vietnam

- Latin America

- - Mexico

- - Brazil

- - Argentina

- Middle East & Africa

- - Turkey

- - Saudi Arabia

- - U.A.E

Global Dendritic Cell Cancer Vaccine Market Insights, Forecast to 2028

Table of Contents
1 Study Coverage
1.1 Dendritic Cell Cancer Vaccine Product Introduction
1.2 Market by Type
1.2.1 Global Dendritic Cell Cancer Vaccine Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 CreaVax
1.2.3 Sipuleucel-T (Provenge)
1.2.4 Others
1.3 Market by Application
1.3.1 Global Dendritic Cell Cancer Vaccine Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Pediatrics
1.3.3 Adults
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Dendritic Cell Cancer Vaccine Sales Estimates and Forecasts 2017-2028
2.2 Global Dendritic Cell Cancer Vaccine Revenue Estimates and Forecasts 2017-2028
2.3 Global Dendritic Cell Cancer Vaccine Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Dendritic Cell Cancer Vaccine Sales by Region
2.4.1 Global Dendritic Cell Cancer Vaccine Sales by Region (2017-2022)
2.4.2 Global Sales Dendritic Cell Cancer Vaccine by Region (2023-2028)
2.5 Global Dendritic Cell Cancer Vaccine Revenue by Region
2.5.1 Global Dendritic Cell Cancer Vaccine Revenue by Region (2017-2022)
2.5.2 Global Dendritic Cell Cancer Vaccine Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Dendritic Cell Cancer Vaccine Sales by Manufacturers
3.1.1 Global Top Dendritic Cell Cancer Vaccine Manufacturers by Sales (2017-2022)
3.1.2 Global Dendritic Cell Cancer Vaccine Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Dendritic Cell Cancer Vaccine in 2021
3.2 Global Dendritic Cell Cancer Vaccine Revenue by Manufacturers
3.2.1 Global Dendritic Cell Cancer Vaccine Revenue by Manufacturers (2017-2022)
3.2.2 Global Dendritic Cell Cancer Vaccine Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Dendritic Cell Cancer Vaccine Revenue in 2021
3.3 Global Dendritic Cell Cancer Vaccine Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Dendritic Cell Cancer Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Dendritic Cell Cancer Vaccine Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Dendritic Cell Cancer Vaccine Sales by Type
4.1.1 Global Dendritic Cell Cancer Vaccine Historical Sales by Type (2017-2022)
4.1.2 Global Dendritic Cell Cancer Vaccine Forecasted Sales by Type (2023-2028)
4.1.3 Global Dendritic Cell Cancer Vaccine Sales Market Share by Type (2017-2028)
4.2 Global Dendritic Cell Cancer Vaccine Revenue by Type
4.2.1 Global Dendritic Cell Cancer Vaccine Historical Revenue by Type (2017-2022)
4.2.2 Global Dendritic Cell Cancer Vaccine Forecasted Revenue by Type (2023-2028)
4.2.3 Global Dendritic Cell Cancer Vaccine Revenue Market Share by Type (2017-2028)
4.3 Global Dendritic Cell Cancer Vaccine Price by Type
4.3.1 Global Dendritic Cell Cancer Vaccine Price by Type (2017-2022)
4.3.2 Global Dendritic Cell Cancer Vaccine Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Dendritic Cell Cancer Vaccine Sales by Application
5.1.1 Global Dendritic Cell Cancer Vaccine Historical Sales by Application (2017-2022)
5.1.2 Global Dendritic Cell Cancer Vaccine Forecasted Sales by Application (2023-2028)
5.1.3 Global Dendritic Cell Cancer Vaccine Sales Market Share by Application (2017-2028)
5.2 Global Dendritic Cell Cancer Vaccine Revenue by Application
5.2.1 Global Dendritic Cell Cancer Vaccine Historical Revenue by Application (2017-2022)
5.2.2 Global Dendritic Cell Cancer Vaccine Forecasted Revenue by Application (2023-2028)
5.2.3 Global Dendritic Cell Cancer Vaccine Revenue Market Share by Application (2017-2028)
5.3 Global Dendritic Cell Cancer Vaccine Price by Application
5.3.1 Global Dendritic Cell Cancer Vaccine Price by Application (2017-2022)
5.3.2 Global Dendritic Cell Cancer Vaccine Price Forecast by Application (2023-2028)
6 North America
6.1 North America Dendritic Cell Cancer Vaccine Market Size by Type
6.1.1 North America Dendritic Cell Cancer Vaccine Sales by Type (2017-2028)
6.1.2 North America Dendritic Cell Cancer Vaccine Revenue by Type (2017-2028)
6.2 North America Dendritic Cell Cancer Vaccine Market Size by Application
6.2.1 North America Dendritic Cell Cancer Vaccine Sales by Application (2017-2028)
6.2.2 North America Dendritic Cell Cancer Vaccine Revenue by Application (2017-2028)
6.3 North America Dendritic Cell Cancer Vaccine Market Size by Country
6.3.1 North America Dendritic Cell Cancer Vaccine Sales by Country (2017-2028)
6.3.2 North America Dendritic Cell Cancer Vaccine Revenue by Country (2017-2028)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Dendritic Cell Cancer Vaccine Market Size by Type
7.1.1 Europe Dendritic Cell Cancer Vaccine Sales by Type (2017-2028)
7.1.2 Europe Dendritic Cell Cancer Vaccine Revenue by Type (2017-2028)
7.2 Europe Dendritic Cell Cancer Vaccine Market Size by Application
7.2.1 Europe Dendritic Cell Cancer Vaccine Sales by Application (2017-2028)
7.2.2 Europe Dendritic Cell Cancer Vaccine Revenue by Application (2017-2028)
7.3 Europe Dendritic Cell Cancer Vaccine Market Size by Country
7.3.1 Europe Dendritic Cell Cancer Vaccine Sales by Country (2017-2028)
7.3.2 Europe Dendritic Cell Cancer Vaccine Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Dendritic Cell Cancer Vaccine Market Size by Type
8.1.1 Asia Pacific Dendritic Cell Cancer Vaccine Sales by Type (2017-2028)
8.1.2 Asia Pacific Dendritic Cell Cancer Vaccine Revenue by Type (2017-2028)
8.2 Asia Pacific Dendritic Cell Cancer Vaccine Market Size by Application
8.2.1 Asia Pacific Dendritic Cell Cancer Vaccine Sales by Application (2017-2028)
8.2.2 Asia Pacific Dendritic Cell Cancer Vaccine Revenue by Application (2017-2028)
8.3 Asia Pacific Dendritic Cell Cancer Vaccine Market Size by Region
8.3.1 Asia Pacific Dendritic Cell Cancer Vaccine Sales by Region (2017-2028)
8.3.2 Asia Pacific Dendritic Cell Cancer Vaccine Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
8.3.12 Philippines
9 Latin America
9.1 Latin America Dendritic Cell Cancer Vaccine Market Size by Type
9.1.1 Latin America Dendritic Cell Cancer Vaccine Sales by Type (2017-2028)
9.1.2 Latin America Dendritic Cell Cancer Vaccine Revenue by Type (2017-2028)
9.2 Latin America Dendritic Cell Cancer Vaccine Market Size by Application
9.2.1 Latin America Dendritic Cell Cancer Vaccine Sales by Application (2017-2028)
9.2.2 Latin America Dendritic Cell Cancer Vaccine Revenue by Application (2017-2028)
9.3 Latin America Dendritic Cell Cancer Vaccine Market Size by Country
9.3.1 Latin America Dendritic Cell Cancer Vaccine Sales by Country (2017-2028)
9.3.2 Latin America Dendritic Cell Cancer Vaccine Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Dendritic Cell Cancer Vaccine Market Size by Type
10.1.1 Middle East and Africa Dendritic Cell Cancer Vaccine Sales by Type (2017-2028)
10.1.2 Middle East and Africa Dendritic Cell Cancer Vaccine Revenue by Type (2017-2028)
10.2 Middle East and Africa Dendritic Cell Cancer Vaccine Market Size by Application
10.2.1 Middle East and Africa Dendritic Cell Cancer Vaccine Sales by Application (2017-2028)
10.2.2 Middle East and Africa Dendritic Cell Cancer Vaccine Revenue by Application (2017-2028)
10.3 Middle East and Africa Dendritic Cell Cancer Vaccine Market Size by Country
10.3.1 Middle East and Africa Dendritic Cell Cancer Vaccine Sales by Country (2017-2028)
10.3.2 Middle East and Africa Dendritic Cell Cancer Vaccine Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Activarti
11.1.1 Activarti Corporation Information
11.1.2 Activarti Overview
11.1.3 Activarti Dendritic Cell Cancer Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Activarti Dendritic Cell Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Activarti Recent Developments
11.2 Argos Therapeutics
11.2.1 Argos Therapeutics Corporation Information
11.2.2 Argos Therapeutics Overview
11.2.3 Argos Therapeutics Dendritic Cell Cancer Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Argos Therapeutics Dendritic Cell Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Argos Therapeutics Recent Developments
11.3 SOTIO (Acquired by PPF Group)
11.3.1 SOTIO (Acquired by PPF Group) Corporation Information
11.3.2 SOTIO (Acquired by PPF Group) Overview
11.3.3 SOTIO (Acquired by PPF Group) Dendritic Cell Cancer Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 SOTIO (Acquired by PPF Group) Dendritic Cell Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 SOTIO (Acquired by PPF Group) Recent Developments
11.4 Bellicum Pharmaceuticals
11.4.1 Bellicum Pharmaceuticals Corporation Information
11.4.2 Bellicum Pharmaceuticals Overview
11.4.3 Bellicum Pharmaceuticals Dendritic Cell Cancer Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Bellicum Pharmaceuticals Dendritic Cell Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Bellicum Pharmaceuticals Recent Developments
11.5 JW CreaGene
11.5.1 JW CreaGene Corporation Information
11.5.2 JW CreaGene Overview
11.5.3 JW CreaGene Dendritic Cell Cancer Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 JW CreaGene Dendritic Cell Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 JW CreaGene Recent Developments
11.6 DanDrit
11.6.1 DanDrit Corporation Information
11.6.2 DanDrit Overview
11.6.3 DanDrit Dendritic Cell Cancer Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 DanDrit Dendritic Cell Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 DanDrit Recent Developments
11.7 DCPrime
11.7.1 DCPrime Corporation Information
11.7.2 DCPrime Overview
11.7.3 DCPrime Dendritic Cell Cancer Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 DCPrime Dendritic Cell Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 DCPrime Recent Developments
11.8 Elios Therapeutics
11.8.1 Elios Therapeutics Corporation Information
11.8.2 Elios Therapeutics Overview
11.8.3 Elios Therapeutics Dendritic Cell Cancer Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Elios Therapeutics Dendritic Cell Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Elios Therapeutics Recent Developments
11.9 ImmunoCellular Therapeutics
11.9.1 ImmunoCellular Therapeutics Corporation Information
11.9.2 ImmunoCellular Therapeutics Overview
11.9.3 ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 ImmunoCellular Therapeutics Recent Developments
11.10 Kiromic
11.10.1 Kiromic Corporation Information
11.10.2 Kiromic Overview
11.10.3 Kiromic Dendritic Cell Cancer Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Kiromic Dendritic Cell Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Kiromic Recent Developments
11.11 Medigene
11.11.1 Medigene Corporation Information
11.11.2 Medigene Overview
11.11.3 Medigene Dendritic Cell Cancer Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Medigene Dendritic Cell Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Medigene Recent Developments
11.12 Merck
11.12.1 Merck Corporation Information
11.12.2 Merck Overview
11.12.3 Merck Dendritic Cell Cancer Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 Merck Dendritic Cell Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Merck Recent Developments
11.13 Northwest Biotherapeutics
11.13.1 Northwest Biotherapeutics Corporation Information
11.13.2 Northwest Biotherapeutics Overview
11.13.3 Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Northwest Biotherapeutics Recent Developments
11.14 Immutep Limited
11.14.1 Immutep Limited Corporation Information
11.14.2 Immutep Limited Overview
11.14.3 Immutep Limited Dendritic Cell Cancer Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.14.4 Immutep Limited Dendritic Cell Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Immutep Limited Recent Developments
11.15 Dendreon Corporation
11.15.1 Dendreon Corporation Corporation Information
11.15.2 Dendreon Corporation Overview
11.15.3 Dendreon Corporation Dendritic Cell Cancer Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.15.4 Dendreon Corporation Dendritic Cell Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 Dendreon Corporation Recent Developments
11.16 Oncobiomed
11.16.1 Oncobiomed Corporation Information
11.16.2 Oncobiomed Overview
11.16.3 Oncobiomed Dendritic Cell Cancer Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.16.4 Oncobiomed Dendritic Cell Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.16.5 Oncobiomed Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Dendritic Cell Cancer Vaccine Industry Chain Analysis
12.2 Dendritic Cell Cancer Vaccine Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Dendritic Cell Cancer Vaccine Production Mode & Process
12.4 Dendritic Cell Cancer Vaccine Sales and Marketing
12.4.1 Dendritic Cell Cancer Vaccine Sales Channels
12.4.2 Dendritic Cell Cancer Vaccine Distributors
12.5 Dendritic Cell Cancer Vaccine Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Dendritic Cell Cancer Vaccine Industry Trends
13.2 Dendritic Cell Cancer Vaccine Market Drivers
13.3 Dendritic Cell Cancer Vaccine Market Challenges
13.4 Dendritic Cell Cancer Vaccine Market Restraints
14 Key Findings in The Global Dendritic Cell Cancer Vaccine Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Tables
Table 1. Global Dendritic Cell Cancer Vaccine Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of CreaVax
Table 3. Major Manufacturers of Sipuleucel-T (Provenge)
Table 4. Major Manufacturers of Others
Table 5. Global Dendritic Cell Cancer Vaccine Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 6. Global Dendritic Cell Cancer Vaccine Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 7. Global Dendritic Cell Cancer Vaccine Sales by Region (2017-2022) & (K Doses)
Table 8. Global Dendritic Cell Cancer Vaccine Sales Market Share by Region (2017-2022)
Table 9. Global Dendritic Cell Cancer Vaccine Sales by Region (2023-2028) & (K Doses)
Table 10. Global Dendritic Cell Cancer Vaccine Sales Market Share by Region (2023-2028)
Table 11. Global Dendritic Cell Cancer Vaccine Revenue by Region (2017-2022) & (US$ Million)
Table 12. Global Dendritic Cell Cancer Vaccine Revenue Market Share by Region (2017-2022)
Table 13. Global Dendritic Cell Cancer Vaccine Revenue by Region (2023-2028) & (US$ Million)
Table 14. Global Dendritic Cell Cancer Vaccine Revenue Market Share by Region (2023-2028)
Table 15. Global Dendritic Cell Cancer Vaccine Sales by Manufacturers (2017-2022) & (K Doses)
Table 16. Global Dendritic Cell Cancer Vaccine Sales Share by Manufacturers (2017-2022)
Table 17. Global Dendritic Cell Cancer Vaccine Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 18. Global Dendritic Cell Cancer Vaccine Revenue Share by Manufacturers (2017-2022)
Table 19. Dendritic Cell Cancer Vaccine Price by Manufacturers (2017-2022) &(USD/Dose)
Table 20. Global Dendritic Cell Cancer Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 21. Global Dendritic Cell Cancer Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Dendritic Cell Cancer Vaccine as of 2021)
Table 22. Dendritic Cell Cancer Vaccine Manufacturing Base Distribution and Headquarters
Table 23. Manufacturers Dendritic Cell Cancer Vaccine Product Offered
Table 24. Date of Manufacturers Enter into Dendritic Cell Cancer Vaccine Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Dendritic Cell Cancer Vaccine Sales by Type (2017-2022) & (K Doses)
Table 27. Global Dendritic Cell Cancer Vaccine Sales by Type (2023-2028) & (K Doses)
Table 28. Global Dendritic Cell Cancer Vaccine Sales Share by Type (2017-2022)
Table 29. Global Dendritic Cell Cancer Vaccine Sales Share by Type (2023-2028)
Table 30. Global Dendritic Cell Cancer Vaccine Revenue by Type (2017-2022) & (US$ Million)
Table 31. Global Dendritic Cell Cancer Vaccine Revenue by Type (2023-2028) & (US$ Million)
Table 32. Global Dendritic Cell Cancer Vaccine Revenue Share by Type (2017-2022)
Table 33. Global Dendritic Cell Cancer Vaccine Revenue Share by Type (2023-2028)
Table 34. Dendritic Cell Cancer Vaccine Price by Type (2017-2022) & (USD/Dose)
Table 35. Global Dendritic Cell Cancer Vaccine Price Forecast by Type (2023-2028) & (USD/Dose)
Table 36. Global Dendritic Cell Cancer Vaccine Sales by Application (2017-2022) & (K Doses)
Table 37. Global Dendritic Cell Cancer Vaccine Sales by Application (2023-2028) & (K Doses)
Table 38. Global Dendritic Cell Cancer Vaccine Sales Share by Application (2017-2022)
Table 39. Global Dendritic Cell Cancer Vaccine Sales Share by Application (2023-2028)
Table 40. Global Dendritic Cell Cancer Vaccine Revenue by Application (2017-2022) & (US$ Million)
Table 41. Global Dendritic Cell Cancer Vaccine Revenue by Application (2023-2028) & (US$ Million)
Table 42. Global Dendritic Cell Cancer Vaccine Revenue Share by Application (2017-2022)
Table 43. Global Dendritic Cell Cancer Vaccine Revenue Share by Application (2023-2028)
Table 44. Dendritic Cell Cancer Vaccine Price by Application (2017-2022) & (USD/Dose)
Table 45. Global Dendritic Cell Cancer Vaccine Price Forecast by Application (2023-2028) & (USD/Dose)
Table 46. North America Dendritic Cell Cancer Vaccine Sales by Type (2017-2022) & (K Doses)
Table 47. North America Dendritic Cell Cancer Vaccine Sales by Type (2023-2028) & (K Doses)
Table 48. North America Dendritic Cell Cancer Vaccine Revenue by Type (2017-2022) & (US$ Million)
Table 49. North America Dendritic Cell Cancer Vaccine Revenue by Type (2023-2028) & (US$ Million)
Table 50. North America Dendritic Cell Cancer Vaccine Sales by Application (2017-2022) & (K Doses)
Table 51. North America Dendritic Cell Cancer Vaccine Sales by Application (2023-2028) & (K Doses)
Table 52. North America Dendritic Cell Cancer Vaccine Revenue by Application (2017-2022) & (US$ Million)
Table 53. North America Dendritic Cell Cancer Vaccine Revenue by Application (2023-2028) & (US$ Million)
Table 54. North America Dendritic Cell Cancer Vaccine Sales by Country (2017-2022) & (K Doses)
Table 55. North America Dendritic Cell Cancer Vaccine Sales by Country (2023-2028) & (K Doses)
Table 56. North America Dendritic Cell Cancer Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 57. North America Dendritic Cell Cancer Vaccine Revenue by Country (2023-2028) & (US$ Million)
Table 58. Europe Dendritic Cell Cancer Vaccine Sales by Type (2017-2022) & (K Doses)
Table 59. Europe Dendritic Cell Cancer Vaccine Sales by Type (2023-2028) & (K Doses)
Table 60. Europe Dendritic Cell Cancer Vaccine Revenue by Type (2017-2022) & (US$ Million)
Table 61. Europe Dendritic Cell Cancer Vaccine Revenue by Type (2023-2028) & (US$ Million)
Table 62. Europe Dendritic Cell Cancer Vaccine Sales by Application (2017-2022) & (K Doses)
Table 63. Europe Dendritic Cell Cancer Vaccine Sales by Application (2023-2028) & (K Doses)
Table 64. Europe Dendritic Cell Cancer Vaccine Revenue by Application (2017-2022) & (US$ Million)
Table 65. Europe Dendritic Cell Cancer Vaccine Revenue by Application (2023-2028) & (US$ Million)
Table 66. Europe Dendritic Cell Cancer Vaccine Sales by Country (2017-2022) & (K Doses)
Table 67. Europe Dendritic Cell Cancer Vaccine Sales by Country (2023-2028) & (K Doses)
Table 68. Europe Dendritic Cell Cancer Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 69. Europe Dendritic Cell Cancer Vaccine Revenue by Country (2023-2028) & (US$ Million)
Table 70. Asia Pacific Dendritic Cell Cancer Vaccine Sales by Type (2017-2022) & (K Doses)
Table 71. Asia Pacific Dendritic Cell Cancer Vaccine Sales by Type (2023-2028) & (K Doses)
Table 72. Asia Pacific Dendritic Cell Cancer Vaccine Revenue by Type (2017-2022) & (US$ Million)
Table 73. Asia Pacific Dendritic Cell Cancer Vaccine Revenue by Type (2023-2028) & (US$ Million)
Table 74. Asia Pacific Dendritic Cell Cancer Vaccine Sales by Application (2017-2022) & (K Doses)
Table 75. Asia Pacific Dendritic Cell Cancer Vaccine Sales by Application (2023-2028) & (K Doses)
Table 76. Asia Pacific Dendritic Cell Cancer Vaccine Revenue by Application (2017-2022) & (US$ Million)
Table 77. Asia Pacific Dendritic Cell Cancer Vaccine Revenue by Application (2023-2028) & (US$ Million)
Table 78. Asia Pacific Dendritic Cell Cancer Vaccine Sales by Region (2017-2022) & (K Doses)
Table 79. Asia Pacific Dendritic Cell Cancer Vaccine Sales by Region (2023-2028) & (K Doses)
Table 80. Asia Pacific Dendritic Cell Cancer Vaccine Revenue by Region (2017-2022) & (US$ Million)
Table 81. Asia Pacific Dendritic Cell Cancer Vaccine Revenue by Region (2023-2028) & (US$ Million)
Table 82. Latin America Dendritic Cell Cancer Vaccine Sales by Type (2017-2022) & (K Doses)
Table 83. Latin America Dendritic Cell Cancer Vaccine Sales by Type (2023-2028) & (K Doses)
Table 84. Latin America Dendritic Cell Cancer Vaccine Revenue by Type (2017-2022) & (US$ Million)
Table 85. Latin America Dendritic Cell Cancer Vaccine Revenue by Type (2023-2028) & (US$ Million)
Table 86. Latin America Dendritic Cell Cancer Vaccine Sales by Application (2017-2022) & (K Doses)
Table 87. Latin America Dendritic Cell Cancer Vaccine Sales by Application (2023-2028) & (K Doses)
Table 88. Latin America Dendritic Cell Cancer Vaccine Revenue by Application (2017-2022) & (US$ Million)
Table 89. Latin America Dendritic Cell Cancer Vaccine Revenue by Application (2023-2028) & (US$ Million)
Table 90. Latin America Dendritic Cell Cancer Vaccine Sales by Country (2017-2022) & (K Doses)
Table 91. Latin America Dendritic Cell Cancer Vaccine Sales by Country (2023-2028) & (K Doses)
Table 92. Latin America Dendritic Cell Cancer Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 93. Latin America Dendritic Cell Cancer Vaccine Revenue by Country (2023-2028) & (US$ Million)
Table 94. Middle East and Africa Dendritic Cell Cancer Vaccine Sales by Type (2017-2022) & (K Doses)
Table 95. Middle East and Africa Dendritic Cell Cancer Vaccine Sales by Type (2023-2028) & (K Doses)
Table 96. Middle East and Africa Dendritic Cell Cancer Vaccine Revenue by Type (2017-2022) & (US$ Million)
Table 97. Middle East and Africa Dendritic Cell Cancer Vaccine Revenue by Type (2023-2028) & (US$ Million)
Table 98. Middle East and Africa Dendritic Cell Cancer Vaccine Sales by Application (2017-2022) & (K Doses)
Table 99. Middle East and Africa Dendritic Cell Cancer Vaccine Sales by Application (2023-2028) & (K Doses)
Table 100. Middle East and Africa Dendritic Cell Cancer Vaccine Revenue by Application (2017-2022) & (US$ Million)
Table 101. Middle East and Africa Dendritic Cell Cancer Vaccine Revenue by Application (2023-2028) & (US$ Million)
Table 102. Middle East and Africa Dendritic Cell Cancer Vaccine Sales by Country (2017-2022) & (K Doses)
Table 103. Middle East and Africa Dendritic Cell Cancer Vaccine Sales by Country (2023-2028) & (K Doses)
Table 104. Middle East and Africa Dendritic Cell Cancer Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 105. Middle East and Africa Dendritic Cell Cancer Vaccine Revenue by Country (2023-2028) & (US$ Million)
Table 106. Activarti Corporation Information
Table 107. Activarti Description and Major Businesses
Table 108. Activarti Dendritic Cell Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 109. Activarti Dendritic Cell Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 110. Activarti Recent Developments
Table 111. Argos Therapeutics Corporation Information
Table 112. Argos Therapeutics Description and Major Businesses
Table 113. Argos Therapeutics Dendritic Cell Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 114. Argos Therapeutics Dendritic Cell Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 115. Argos Therapeutics Recent Developments
Table 116. SOTIO (Acquired by PPF Group) Corporation Information
Table 117. SOTIO (Acquired by PPF Group) Description and Major Businesses
Table 118. SOTIO (Acquired by PPF Group) Dendritic Cell Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 119. SOTIO (Acquired by PPF Group) Dendritic Cell Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 120. SOTIO (Acquired by PPF Group) Recent Developments
Table 121. Bellicum Pharmaceuticals Corporation Information
Table 122. Bellicum Pharmaceuticals Description and Major Businesses
Table 123. Bellicum Pharmaceuticals Dendritic Cell Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 124. Bellicum Pharmaceuticals Dendritic Cell Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 125. Bellicum Pharmaceuticals Recent Developments
Table 126. JW CreaGene Corporation Information
Table 127. JW CreaGene Description and Major Businesses
Table 128. JW CreaGene Dendritic Cell Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 129. JW CreaGene Dendritic Cell Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 130. JW CreaGene Recent Developments
Table 131. DanDrit Corporation Information
Table 132. DanDrit Description and Major Businesses
Table 133. DanDrit Dendritic Cell Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 134. DanDrit Dendritic Cell Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 135. DanDrit Recent Developments
Table 136. DCPrime Corporation Information
Table 137. DCPrime Description and Major Businesses
Table 138. DCPrime Dendritic Cell Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 139. DCPrime Dendritic Cell Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 140. DCPrime Recent Developments
Table 141. Elios Therapeutics Corporation Information
Table 142. Elios Therapeutics Description and Major Businesses
Table 143. Elios Therapeutics Dendritic Cell Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 144. Elios Therapeutics Dendritic Cell Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 145. Elios Therapeutics Recent Developments
Table 146. ImmunoCellular Therapeutics Corporation Information
Table 147. ImmunoCellular Therapeutics Description and Major Businesses
Table 148. ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 149. ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 150. ImmunoCellular Therapeutics Recent Developments
Table 151. Kiromic Corporation Information
Table 152. Kiromic Description and Major Businesses
Table 153. Kiromic Dendritic Cell Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 154. Kiromic Dendritic Cell Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 155. Kiromic Recent Developments
Table 156. Medigene Corporation Information
Table 157. Medigene Description and Major Businesses
Table 158. Medigene Dendritic Cell Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 159. Medigene Dendritic Cell Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 160. Medigene Recent Developments
Table 161. Merck Corporation Information
Table 162. Merck Description and Major Businesses
Table 163. Merck Dendritic Cell Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 164. Merck Dendritic Cell Cancer Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 165. Merck Recent Developments
Table 166. Northwest Biotherapeutics Corporation Information
Table 167. Northwest Biotherapeutics Description and Major Businesses
Table 168. Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022
  • Global BCG Vaccine Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 96
    According to our LPI (LP Information) latest study, the global BCG Vaccine market size was valued at US$ 365.6 million in 2023. With growing demand in downstream market, the BCG Vaccine is forecast to a readjusted size of US$ 542.8 million by 2030 with a CAGR of 5.8% during review period. The research report highlights the growth potential of the global BCG Vaccine market. BCG Vaccine are expected to show stable growth in the future market. However, product differentiation, reducing cost......
  • Global Peptide Cancer Vaccine Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 115
    According to our LPI (LP Information) latest study, the global Peptide Cancer Vaccine market size was valued at US$ 535 million in 2023. With growing demand in downstream market, the Peptide Cancer Vaccine is forecast to a readjusted size of US$ 1978.2 million by 2030 with a CAGR of 20.5% during review period. The research report highlights the growth potential of the global Peptide Cancer Vaccine market. Peptide Cancer Vaccine are expected to show stable growth in the future market. How......
  • Global Cancer Vaccine Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 26-Dec-2023        Price: US 3380 Onwards        Pages: 101
    Market Overview of Global Cancer Vaccine market: According to our latest research, the global Cancer Vaccine market looks promising in the next 5 years. As of 2022, the global Cancer Vaccine market was estimated at USD 7198.2 million, and it's anticipated to reach USD 33936.62 million in 2028, with a CAGR of 29.49% during the forecast years. A cancer vaccine is a type of immunotherapy that boost the body's natural defenses by stimulating the immune system to recognize and cur......
  • Global Lung Cancer Vaccines Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 12-Dec-2023        Price: US 3380 Onwards        Pages: 102
    Market Overview of Global Lung Cancer Vaccines market: According to our latest research, the global Lung Cancer Vaccines market looks promising in the next 5 years. As of 2022, the global Lung Cancer Vaccines market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. Lung Cancer Vaccines,A cancer vaccine for lung cance This report covers a research time span from 2018 to 2028, and ......
  • Global Cancer Vaccines Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 07-Dec-2023        Price: US 3380 Onwards        Pages: 105
    Market Overview of Global Cancer Vaccines market: According to our latest research, the global Cancer Vaccines market looks promising in the next 5 years. As of 2022, the global Cancer Vaccines market was estimated at USD 5773.14 million, and it's anticipated to reach USD 15406.41 million in 2028, with a CAGR of 17.77% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Cancer Vacci......
  • Global Dendritic Cell Cancer Vaccine Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 16-Nov-2023        Price: US 3380 Onwards        Pages: 110
    Market Overview of Global Dendritic Cell Cancer Vaccine market: According to our latest research, the global Dendritic Cell Cancer Vaccine market looks promising in the next 5 years. As of 2022, the global Dendritic Cell Cancer Vaccine market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. Dendritic cells (DC) are one of the major antigen presenting cells found in lymphoid organs. The main fu......
  • Global BCG Vaccine Market Research Report 2023, Forecast to 2028
    Published: 14-Nov-2023        Price: US 2680 Onwards        Pages: 135
    BCG Vaccine is not given as part of the routine NHS vaccination schedule. It's given on the NHS only when a child or adult is thought to have an increased risk of coming into contact with TB. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage o......
  • Global BCG Vaccine Professional Survey Report 2023, Forecast to 2028
    Published: 14-Nov-2023        Price: US 3280 Onwards        Pages: 105
    BCG Vaccine is not given as part of the routine NHS vaccination schedule. It's given on the NHS only when a child or adult is thought to have an increased risk of coming into contact with TB. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage o......
  • Infectious Vaccine Collaboration and Licensing Deals 2016-2023
    Published: 01-Nov-2023        Price: US 3995 Onwards        Pages: 300
    Infectious Vaccine Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the infectious vaccine deals entered into by the worlds leading biopharma companies. Fully revised and updated, the report provides details of infectious vaccine deals from 2016 to 2023. The report provides a detailed understanding and analysis of how and why companies enter infectious vaccine deals. These deals tend to be multicomponent, starting with......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs